UPDATE: Garmin (GRMN) to replace RR Donnelly in S&P 500
Tweet
Share
E-mailGet Alerts GRMN Hot Sheet
Price: $143.03 +0.17%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 2.8%
Revenue Growth %: +8.7%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 2.8%
Revenue Growth %: +8.7%
Join SI Premium – FREE
(Updated - December 5, 2012 5:22 PM EST)
Garmin (NASDAQ: GRMN) to replace RR Donnelley (NASDAQ: RRD) in S&P 500 and RR Donnelley will replace Medicis Pharmaceutical Corp. (NYSE: MRX) in the S&P MidCap 400 after the close of trading Tuesday, December 11.
Valeant Pharmaceuticals International Inc. (NYSE:VRX) is acquiring Medicis.
Garmin (NASDAQ: GRMN) to replace RR Donnelley (NASDAQ: RRD) in S&P 500 and RR Donnelley will replace Medicis Pharmaceutical Corp. (NYSE: MRX) in the S&P MidCap 400 after the close of trading Tuesday, December 11.
Valeant Pharmaceuticals International Inc. (NYSE:VRX) is acquiring Medicis.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ByteDance Prefers TikTok Shutdown in US if Legal Options Fail - Reuters
- GE Aerospace (GE) PT Raised to $180 at BofA Securities
- SEI Investments (SEIC) PT Lowered to $69 at Piper Sandler
Create E-mail Alert Related Categories
Trader TalkRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
